Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296218 · ClinicalTrials.gov registry record · Phase 3
ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
NCT00296218 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 440 participants.
The verdict
NCT00296218, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
Study Summary
Primary Objective * The main objective of this study is to assess if a two-month regimen of irbesartan in patients hospitalized for acute coronary syndrome without ST segment elevation can reduce inflammation markers (ie hsCRP), in comparison to a similar regimen of enalapril. Secondary Objectives * To compare both regimens on several other biological parameters which have demonstrated their relevance and their predictive clinical value (ie BNP, microalbuminuria, troponin I …) in this patient population. * To compare on the above parameters the early initiation of treatment versus the initiation of treatment at hospital discharge.
Interventions
- DRUG Irbesartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00296218
The ClinicalTrials.gov registry entry for NCT00296218 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irbesartan is the first listed.
NCT00296218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00296218 about?
NCT00296218 is a clinical study titled "ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation". Primary Objective * The main objective of this study is to assess if a two-month regimen of irbesartan in patients hospitalized for acute coronary syndrome without ST segment elevation can reduce inflammation markers (ie hsCRP), in comparison to a similar regimen of enalapril. Secondary Objectives...
What is the current status of trial NCT00296218?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2006-02.
What interventions are being tested in trial NCT00296218?
The interventions under investigation include: Irbesartan (DRUG).
Who is sponsoring clinical trial NCT00296218?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.